Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Pennsylvania’s universities - Pitt, UPenn and Penn State in particular - have big reputations, and to back them up, they ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Emcure Pharmaceuticals posted a 35.4 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 153.7 crore ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Read on to learn more about the six Australian and New Zealand startups that raised $234.2 million in the legal, healthcare ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

But now, thanks to a combination of non-profit researchers and African public-health workers, there are signs of progress ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

The Conference Forum today announced the launch of the 9th annual Patients as Partners® Europe event, taking place on May 20-21, 2025 at Royal National Hotel in London, UK. The meeting offers an ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...